Amgen 2000 Annual Report Download - page 18

2120
Amgen late-stage Amgen early-stage
Disease Description Amgen products 1product candidates 2product candidates 3
INFLAMMATION
Rheumatoid arthritis A disease characterized by pain and Anakinra Soluble tumor
swelling of the joints in which the body’s (Interleukin-1 necrosis factor-
natural immune system attacks healthy receptor receptor type I
joint tissue as it would foreign cells antagonist, IL-1ra) (sTNF-RI)
NEUROLOGY/METABOLISM
Obesity The storage of excess fat in the body Leptin
Parkinson’s disease A motor system disorder characterized Neuroimmuno-
by tremors of hands, arms, legs, jaw, philin program
and face; stiffness of the limbs and
trunk; slowness of movement; and
impaired balance and coordination
OTHER
Osteoporosis A disease of the skeleton in which the Osteoprotegerin
amount of calcium present in the (OPG) program
bones slowly decreases to the point
where the bones become brittle and
prone to fracture
Endometriosis A painful disease wherein fragments Abarelix-depot
of endometrial tissue implant outside
the uterine cavity, usually in other
areas of the pelvis, in women
Primary Excessive production of parathyroid Calcimimetic
hyperparathyroidism hormone by a benign tumor program
Hepatitis C A liver disease caused by the INFERGEN ®
hepatitis C virus (HCV), which is (Interferon
found in the blood of persons who alfacon-1)
have this disease
1Denotes marketed products in the United States and other countries.
2Denotes product candidates in phase 3 clinical trials or filed with regulatory agencies.
3Denotes product candidates in phase 1 or 2 clinical trials.
4STEMGEN®is marketed in Canada and Australia only.
The Company’s ability to develop and commercialize new products is highly uncertain because very few pharmaceutical/biotechnology research and development products
ever produce a commercial product. In addition, while the Company routinely seeks to obtain patents for its products, the protection offered by patents and patent appli-
cations may be challenged, invalidated, or circumvented. The Company believes that in some cases third party patent rights could limit product commercialization.
Amgen late-stage Amgen early-stage
Disease Description Amgen products 1product candidates 2product candidates 3
CHRONIC KIDNEY DISEASE
Anemia A decrease in the normal amounts EPOGEN ®ARANESP TM
of red blood cells that develops in (Epoetin alfa) (darbepoetin
chronic kidney disease patients due alfa)
to a decrease in the production of
erythropoietin by the kidneys
Secondary Excessive production of parathyroid Calcimimetic
hyperparathyroidism hormone program
CANCER
Neutropenia A decrease in a type of white blood NEUPOGEN ®SD/01
cell called a neutrophil that may occur (Filgrastim)
following chemotherapy treatment
resulting in an increased risk of
infection
Anemia A decrease in the normal amount ARANESP ®
of red blood cells that may occur (darbepoetin alfa)
following chemotherapy treatment
or due to the cancer itself
Stem cell A procedure in which the bone NEUPOGEN ®
transplantation marrow destroyed by high doses (Filgrastim)
of chemotherapy or radiation is STEMGEN ®
replaced by stem cells that (Ancestim) 4
produce white blood cells, red
blood cells, and platelets
Aplastic anemia A failure of the bone marrow to STEMGEN ®
generate cells (Ancestim)
Mucositis Inflammation of the mucosal lining Keratinocyte
of the gastrointestinal tract as a growth factor
result of cancer treatment (KGF)
Bone metastases Invasion of bone by cancer cells Osteoprotegerin
originating in other parts of the body (OPG) program
that may induce bone destruction
Prostate cancer A slow-growing malignant tumor in men Abarelix-depot
that arises in the prostate gland and can
spread to other parts of the body
Non-Hodgkin’s A heterogeneous group of Epratuzumab
lymphoma lymphoproliferative malignancies that
usually originate in lymphoid tissues
and may spread to other organs
Amgen is discovering and developing a stream of product candidates using science and innovation to dramatically improve people’s lives.
By leveraging its core biology and protein expertise and aggressively pursuing outside innovation, Amgen’s research and development strategy
is focused on four main therapeutic areas—chronic kidney disease, cancer, inflammation, and neurology/metabolism—and three potential
patient-delivery modalities—protein, small-molecule, and antibody therapeutics.
Amgen Products and Product Candidates